Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective

DOI: 10.1371/journal.pone.0172731

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text